BANK VONTOBEL/CALL/MODERNA/150/0.1/20.12.24 | Market Closed - Euronext Paris 12:30:00 2024-06-26 pm EDT | ||
| 1.27 EUR | -21.12% |
|
| Current month | -35.29% | ||
| 1 month | -64.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 1.32 | -18.01% |
| 24-06-25 | 1.61 | -0.62% |
| 24-06-24 | 1.62 | +5.19% |
| 24-06-21 | 1.54 | +2.67% |
| 24-06-20 | 1.5 | +4.90% |
Real-time Euronext Paris
Last update June 26, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| PQ48V | |
| ISIN | DE000VM7WHC8 |
| Date issued | 2024-01-04 |
| Strike | 150 $ |
| Maturity | 2024-12-20 (177 Days) |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.81 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.02 € |
| Spread % | 1.56% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4
USD
Average target price
145.9
USD
Spread / Average Target
+19.11%
- Stock Market
- Warrants
- PQ48V Warrant
